You are here
Bayer's drug sales in Asia-Pac up 8.6% in 2016
PHARMACEUTICAL company Bayer reported an 8.6 per cent increase to 4.8 billion euros (S$7.21 billion) in drug sales in the Asia-Pacific region in 2016.
This is its sixth consecutive year of growth - nearly doubled from 2.6 billion euros in 2010.
Claus Zieler, Bayer's senior vice-president and head of commercial operations at its Asia-Pacific pharmaceutical division, said innovation is the foundation of his company's success.
"Our portfolio of innovative medicines, which addresses the unmet medical needs of patients in the Asia-Pacific region, drives our strong business growth today," he said.
Bayer expects global sales of more than 17 billion euros for its pharmaceuticals division in 2017.